Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NGR-hTNF + cisplatin
- Development stage
- Phase 1
- Lead developer
- AGC Biologics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
NGR-hTNF + cisplatin is a combination regimen composed of **NGR-hTNF**, a recombinant fusion protein consisting of human tumor necrosis factor-α (TNF) fused to the tumor-homing peptide asparagine–glycine–arginine (NGR), and **cisplatin**, a platinum-based chemotherapeutic agent. The NGR motif targets aminopeptidase N (CD13) isoforms overexpressed on angiogenic tumor endothelium, enhancing selective delivery of TNF to tumor vasculature and rapidly increasing vascular permeability. This facilitates the enhanced uptake of cisplatin (and other chemotherapeutics) into tumors. NGR-hTNF promotes apoptosis of tumor endothelial cells, reduces interstitial fluid pressure, enables improved chemotherapeutic delivery, and may promote antitumor immune responses. In clinical studies, the combination shows promising antitumor activity and favorable tolerability in patients with advanced chemoresistant malignancies[1][2][4].
- Other names
- asparagine-glycine-arginine-human tumor necrosis factor + cisplatin
02
Targets
ANPEP (Aminopeptidase N)DNATNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)TNFR2 (Tumor necrosis factor receptor superfamily member 1B)
Beyond the preview
Go deeper on NGR-hTNF + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGR-hTNF + cisplatin.